AbCellera Biologics Inc (NASDAQ:ABCL) saw a downside of -1.47% to close Tuesday at $4.70 after subtracting -$0.07 on the day. The 5-day average trading volume is 2,162,700 shares of the company’s common stock. It has gained $5.30 in the past week and touched a new high 1 time within the past 5 days. An average of 1,722,145 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,879,600.
ABCL’s 1-month performance is -14.70% or -$0.81 on its low of $4.67 reached on 09/26/23. The company’s shares have touched a 52-week low of $4.75 and high of $14.97, with the stock’s rally to the 52-week high happening on 02/03/23. YTD, ABCL has lost -53.60% or -$5.43 and has reached a new high 7 times. However, the current price is down -68.60% from the 52-week high price.
Valuation Metrics
ABCL stock has a beta of 0.06. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 9.37 while the price-to-book (PB) in the most recent quarter is 1.13.
AbCellera Biologics Inc’s quick ratio for the period ended June 29 was 7.82, with the current ratio over the same period at 7.83. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.07, while the total debt to equity was 0.07. The trailing 12-month EBITDA margin is 65.11% while for the period ending June 29, AbCellera Biologics Inc’s operating margin was -68.69%. The firm’s gross profit as reported stood at $268.91 million against revenue of $485.42 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 77.76% to -$30.53 million, while revenue of -$40.11 million was -31.38% off the previous quarter. Analysts expected ABCL to announce -$0.13 per share in earnings in its latest quarter, but it posted -$0.11, representing a 15.40% surprise. EBITDA for the quarter stood at more than -$44.13 million. ABCL stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 342.34 million, with total debt at $84.03 million. Shareholders hold equity totaling $289.36 million.
Let’s look briefly at AbCellera Biologics Inc (ABCL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 26 September was 25.53% to suggest the stock is trending oversold, with historical volatility in this time period at 43.28%.
The stock’s 5-day moving average is $4.89, reflecting a -7.48% or -$0.38 change from its current price. ABCL is currently trading -14.55% above its 20-day SMA, -28.68% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -37.75% and SMA200 by-57.81%.
Stochastic %K and %D was 6.23% and 6.15% and the average true range (ATR) pointed at 0.21. The RSI (14) points at 28.97%, while the 14-day stochastic is at 3.19% with the period’s ATR at 0.22. The stock’s 9-day MACD Oscillator is pointing at -0.20 and -0.31 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for AbCellera Biologics Inc (NASDAQ: ABCL), Cowen launched coverage with an Outperform rating. Analysts offering their rating for ABCL stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ABCL as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 8 have offered a “buy” rating.
What is ABCL’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $12.00 and a high of $34.00, with their median price target at $28.00. Looking at these predictions, the average price target given by analysts is for AbCellera Biologics Inc (ABCL) stock is $24.43.
